Trinucleotide mRNA Cap Analog for Transcription Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cap analogs for in vitro mRNA synthesis, such as m7G(5′)p3, face challenges in achieving efficient transcription and translation due to competition with guanine nucleotides and issues with reverse orientation of cap structures, leading to less than half of mRNA products having a cap structure at their 5′ termini.
Innovation Solution
Development of trinucleotide cap analogs, specifically m7G(5′)p3-N1pN2, where m7G is linked to a triphosphate bridge connected to ribonucleotides N1 and N2, with modified bases and riboses, including fluoro or alkoxy substituents, to enhance transcriptional efficiency and orientation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If m7G(5′)p3 is used as cap analog, then transcription can be initiated, but competition with guanine nucleotide results in less than half of mRNA having cap structure
Solution Approach 1:
The cap analog is segmented into a trinucleotide structure (m7G-N1-N2) rather than a simple dinucleotide, allowing the first nucleotide (m7G) to serve as the cap structure while the subsequent nucleotides (N1, N2) are positioned to prevent reverse orientation and compete effectively against guanine nucleotides for transcription initiation
Solution Approach 2:
Specific nucleotides within the trinucleotide cap analog are modified with specific bases (N1, N2) and chemical modifications (2′-O-methyl, fluoro, alkoxy substituents) to locally enhance the cap's ability to bind translation initiation factors and prevent reverse orientation, while maintaining the overall cap structure function
2Productivity
If dinucleotide cap analogs are used, then transcription initiation is achieved, but reverse orientation of cap structures occurs
Solution Approach 1:
The cap analog employs an asymmetric trinucleotide structure where the first nucleotide (m7G) is distinct from the second and third nucleotides (N1, N2). This asymmetry prevents reverse orientation by creating a directional structure that can bind translation initiation factors only in the correct orientation, thereby ensuring manufacturing precision of cap orientation
Solution Approach 2:
The cap analog is designed with pre-positioned nucleotides (N1, N2) that are already in the correct orientation and configuration to prevent reverse orientation during transcription initiation, rather than relying on post-initiation correction mechanisms
3Productivity
If modified riboses and bases are introduced, then transcriptional efficiency is enhanced, but structural complexity increases
Solution Approach 1:
The patent introduces specific chemical modifications to the ribose and base components of the cap analog (such as 2′-O-methyl groups, fluoro substituents, alkoxy groups, and modified bases like N6-methyladenine) to change the physical and chemical parameters of the cap structure, thereby enhancing transcriptional efficiency and translation initiation while maintaining manageable structural complexity through systematic modification approaches
Data Source
AI summary
What is described is a trinucleotide cap analog comprising m7G(5′)p3-N1pN2 for increased efficiency of in vitro transcription of m7G(5′)p3-RNA, wherein m7G is N7-methylguanosine or analog, (5′)p3 is a 5′,5′-triphosphate bridge, and N1 or N2 or both ribonucleotide analogs linked to each other by a phosphate, p, and wherein the trinucleotide cap analog increases the efficiency of in vitro transcription.